Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 13, 2022 at 08:40 pm EST
Share
Euro-Med Laboratories Phil., Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was PHP 981.01 million compared to PHP 949.44 million a year ago. Net income was PHP 56.69 million compared to PHP 53.43 million a year ago. Basic earnings per share from continuing operations was PHP 0.01 compared to PHP 0.01 a year ago. Diluted earnings per share from continuing operations was PHP 0.01 compared to PHP 0.01 a year ago.
For the nine months, sales was PHP 2,627.57 million compared to PHP 2,604.43 million a year ago. Net income was PHP 111.46 million compared to PHP 105.74 million a year ago. Basic earnings per share from continuing operations was PHP 0.03 compared to PHP 0.03 a year ago. Diluted earnings per share from continuing operations was PHP 0.03 compared to PHP 0.03 a year ago.
Euro-Med Laboratories Phil., Inc. is a Philippines-based company, which is engaged in the manufacturing of pharmaceutical products, such as large and small-volume parenteral and other solutions, inhalation, irrigation, and dialysis. It also manufactures sterile water for injection, and other solutions, such as ophthalmic, inhalation, irrigation and dialysis. The Company's segments include manufacturing pharmaceutical products, providing health and other care services, and development and operation of quick service restaurants. Its subsidiaries include Hemotek Renal Center, Inc. (Hemotek), and CafeFrance Corp (CafeFrance). Hemotek provides renal and other healthcare services and is engaged as a dialysis center. CafeFrance is engaged in the development and operation of quick service restaurant (QSR). CafeFrance is engaged in operating restaurants, bakeries, food services, catering, food production and other related services incidental thereto.
EURO-MED LABORATORIES PHIL., INC. 
